GANX, NGM

Gain Therapeutics, Inc. (GANX)

Price (as of September 27)

3.28USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

REGN

Regeneron Pharmaceuticals, Inc.

-0.14

BBIO

BridgeBio Pharma, Inc.

-0.13

BTTX

Better Therapeutics, Inc.

-0.12

RXRX

Recursion Pharmaceuticals, Inc.

-0.1

ASND

Ascendis Pharma A/S

-0.09

CBIO

Catalyst Biosciences, Inc.

-0.09

BNTX

BioNTech SE

-0.09

ABCM

Abcam plc

-0.09

CELC

Celcuity Inc.

-0.09

ANEB

Anebulo Pharmaceuticals, Inc.

-0.09

Show more

Highest within Industry

Symbol Correlation

ALLR

Allarity Therapeutics, Inc.

0.18

ADTX

Aditxt, Inc.

0.14

ACIU

AC Immune SA

0.13

ADPT

Adaptive Biotechnologies Corporation

0.13

AKBA

Akebia Therapeutics, Inc.

0.12

AIM

AIM ImmunoTech Inc.

0.12

ATAI

Atai Life Sciences N.V.

0.12

BEAM

Beam Therapeutics Inc.

0.12

BNOX

Bionomics Limited

0.11

CYCC

Cyclacel Pharmaceuticals, Inc.

0.11

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.